Literature DB >> 15900181

Prediction of costs-of-illness in patients with low back pain undergoing orthopedic outpatient rehabilitation.

Sonja Merkesdal1, Wilfried Mau.   

Abstract

The objectives of this study were (1) to assess societal costs-of-illness and their changes in the year prior to and after outpatient rehabilitation (OPR) in initially gainfully employed persons with low back pain and (2) to identify predictors (cost drivers) for high overall costs in the year after the intervention. The health economical analysis is part of a prospective clinical trial investigating patients participating in orthopedic OPR. In all gainfully employed patients (n=244) resource consumption and productivity losses were assessed prior to OPR and 12 months afterwards. Overall annual medical costs per person were estimated. Parameters associated with high overall costs in the 12 months after OPR were predicted by multivariate logistic regression analysis. All sociodemographic, motivational, clinical, psychological, therapeutic and vocational variables were included as possible predictors. Costs due to sick leave periods represent the major component (83%/58%) of overall costs in both periods. The comparison of costs 12 months before and after OPR reveals a significant reduction from 8050 to 3200 per person, primarily caused by decreasing sick leave costs and the reduction of costs related to inpatient treatment. The prediction analysis reveals that patients with limited functional abilities, with problems due to strenuous labour, with low expectations in terms of possible improvement after OPR, with a high pain score or with limited satisfaction with working colleagues have a significantly higher risk for costs exceeding 2200 after OPR. The identified cost drivers can be used to develop multimodal therapeutic measures, which should be employed during the OPR intervention in order to prevent future costs.

Entities:  

Mesh:

Year:  2005        PMID: 15900181     DOI: 10.1097/00004356-200506000-00004

Source DB:  PubMed          Journal:  Int J Rehabil Res        ISSN: 0342-5282            Impact factor:   1.479


  7 in total

1.  Responsiveness of the Chinese version of the Oswestry disability index in patients with chronic low back pain.

Authors:  Chao Ma; Shaoling Wu; Lingjun Xiao; Yunlian Xue
Journal:  Eur Spine J       Date:  2010-11-26       Impact factor: 3.134

2.  Exercise prescription for chronic back or neck pain: who prescribes it? who gets it? What is prescribed?

Authors:  Janet K Freburger; Timothy S Carey; George M Holmes; Andrea S Wallace; Liana D Castel; Jane D Darter; Anne M Jackman
Journal:  Arthritis Rheum       Date:  2009-02-15

3.  Risk factors for back pain-related loss of working time after surgery for lumbar disc herniation: a 5-year follow-up study.

Authors:  K Puolakka; J Ylinen; M H Neva; H Kautiainen; A Häkkinen
Journal:  Eur Spine J       Date:  2007-11-23       Impact factor: 3.134

Review 4.  Systematic review of the ability of recovery expectations to predict outcomes in non-chronic non-specific low back pain.

Authors:  Ross A Iles; Megan Davidson; Nicholas F Taylor; Paul O'Halloran
Journal:  J Occup Rehabil       Date:  2009-01-06

5.  Effect of thermal therapy and exercises on acute low back pain: a protocol for a randomized controlled trial.

Authors:  Claudia Côté-Picard; Jean Tittley; Catherine Mailloux; Kadija Perreault; Catherine Mercier; Clermont E Dionne; Jean-Sébastien Roy; Hugo Massé-Alarie
Journal:  BMC Musculoskelet Disord       Date:  2020-12-05       Impact factor: 2.362

6.  Identifying heavy health care users among primary care patients with chronic non-cancer pain.

Authors:  Elie Antaky; Lyne Lalonde; Mireille E Schnitzer; Élisabeth Martin; Djamal Berbiche; Sylvie Perreault; David Lussier; Manon Choinière
Journal:  Can J Pain       Date:  2017-07-06

7.  Factors associated with persistently high-cost health care utilization for musculoskeletal pain.

Authors:  Trevor A Lentz; Jeffrey S Harman; Nicole M Marlow; Jason M Beneciuk; Roger B Fillingim; Steven Z George
Journal:  PLoS One       Date:  2019-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.